Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patient consent~* Patient must be seven years of age or older~* Patient must have documented biochemical or genetic proof of MPS VI~* The patient must be able to walk independently at least 5 meters and no more than 270 meters in the first 6 minutes, or no more then 400 meters total in 12 minutes, in the screening 12-minute walk test~* If female of childbearing potential, patient must have a negative pregnancy test~Exclusion Criteria~* Patient is under consideration for or has undergone a successful bone marrow transplant (BMT)~* Patient refuses or is unable to complete all screening evaluations~* Pregnant or lactating patient~* Patient has received an investigational drug within 30 days prior to study enrollment~* Patient has been previously treated with rhASB~* Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance~* The patient has clinically significant spinal cord compression~* The patient has known hypersensitivity to rhASB or to components of the active or placebo test solutions

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- rhASB (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).